Sign in

    Sarah Schram • William Blair

    Sarah Schram's questions to Xenon Pharmaceuticals Inc (XENE) leadership

    Sarah Schram's questions to Xenon Pharmaceuticals Inc (XENE) leadership • Q4 2024

    Question

    Sarah Schram from William Blair asked if Azetukalner could show benefits on mania in the bipolar depression study and questioned the development strategy for the preclinical Nav1.1 program, including its potential beyond Dravet syndrome.

    Answer

    CMO Dr. Chris Kenney explained that a study in bipolar depression enrolls non-manic patients, so it is not designed to measure or show a benefit in mania. CEO Ian Mortimer addressed the Nav1.1 program, stating the initial focus is Dravet syndrome due to the direct genetic link. He highlighted compelling preclinical data suggesting disease-modifying potential and noted that while the initial focus is Dravet, the mechanism could have broader utility in other epilepsies.

    Ask Fintool Equity Research AI

    Sarah Schram's questions to Xenon Pharmaceuticals Inc (XENE) leadership • Q3 2024

    Question

    Sarah Schram asked whether Xenon plans to pursue both acute and chronic pain indications for its Nav1.7 inhibitor and if the company would ever consider developing a Nav1.8 inhibitor.

    Answer

    CEO Ian Mortimer responded that the Nav1.7 target is applicable to both acute and chronic pain, so while the initial proof-of-concept study will be in acute pain (bunionectomy), all later-stage indications remain possibilities. He confirmed Xenon is focused on Nav1.7 due to stronger genetic validation and its leadership position, and does not have a formal Nav1.8 program.

    Ask Fintool Equity Research AI